AIDS Malignancy Clinical Trials Consortium

艾滋病恶性肿瘤临床试验联盟

基本信息

项目摘要

DESCRIPTION (provided by applicant): The Group Chair' office of the AIDS Malignancy Consortium (AMC) is located in the UCLA Center for Clinical AIDS Research and Education (CARE Center), located at 9911 Pico Blvd, Ste 980, Los Angeles, CA 90035. The AMC is a clinical trials cooperative group established to evaluate new clinical interventions for the treatment and prevention of malignancies in HIV. The mission of the AMC is to improve the therapy of malignancies in HIV and to develop new and more effective treatment and prevention approaches. Dr. Ronald Mitsuyasu, the AMC Group Chair, is Director of the UCLA CARE Center and Professor of Medicine in the Division of Hematology-Oncology at UCLA. Dr. Mitsuyasu is responsible for the coordination, overall function, scientific direction, and fiscal accountability of the AMC. With input from the AMC working groups, Executive Committee and NCI Program Director, he sets the scientific agenda and oversees the execution of the AMC's protocols and other scientific endeavors. He chairs all meetings and conference calls of the Executive and Steering Committees, interacts with all components of the AMC and is the primary representative of the group to other oncology and HIV clinical trials groups, the AIDS Cancer and Specimen Resource (ACSR) and the NIAID Managing Partner Committee. Dr. Mitsuyasu will be assisted by a Project Manager who will coordinate the functions of the various group components and will maintain communications between the Group Chair and the sites, operations center, statistics center and core labs. She will also represent the Group Chair on working group calls and review protocols for accuracy and completeness prior to their being released to the sites. A project assistant will arrange and take minutes for all AMC conference calls and perform secretarial duties for the Group Chair and Project Manager. A project analyst will be responsible for monitoring all aspects of the finances of the group and preparing fiscal reports for the NCI. Malignancies are a growing problem in immune deficient HIV patients, and cancer remains one of the major causes of morbidity and mortality in AIDS patients. The AIDS Malignancy Consortium (AMC) conducts studies to improve the treatment of cancers in HIV disease. The AMC Group Chair's office is responsible for coordinating and overseeing all aspects of the functioning of the AMC.
描述(由申请人提供):艾滋病恶性财团(AMC)的小组主席办公室位于UCLA临床艾滋病研究和教育中心(CARE CENTER(CARE CENTER),位于9911 Pico Blvd,Ste 980,洛杉矶,CA 90035。 AMC的任务是改善艾滋病毒恶性肿瘤的治疗,并开发新的,更有效的治疗方法和预防方法。 AMC集团主席Ronald Mitsuyasu博士是UCLA护理中心主任,也是UCLA血液肿瘤学系的医学教授。 Mitsuyasu博士负责AMC的协调,整体功能,科学方向和财政责任制。在AMC工作组,执行委员会和NCI计划主管的意见下,他设定了科学议程,并监督了AMC协议和其他科学努力的执行。他主持了执行和指导委员会的所有会议和会议,与AMC的所有组成部分进行互动,并且是其他肿瘤学和HIV临床试验小组的主要代表,AIDS癌症和标本资源(ACSR)和NIAID管理伙伴委员会。 Mitsuyasu博士将得到项目经理的协助,该项目经理将协调各个小组组件的功能,并将维护小组主席与网站,运营中心,统计中心和核心实验室之间的通信。她还将代表小组主席的工作组电话和审查协议,以获取准确性和完整性,然后再将其释放到网站。一名项目助理将安排并花几分钟的时间参加所有AMC电话会议,并为团体主席和项目经理履行秘书职责。项目分析师将负责监视小组财务的各个方面并为NCI准备财政报告。 恶性肿瘤是免疫缺陷HIV患者的日益严重的问题,癌症仍然是艾滋病患者发病和死亡率的主要原因之一。艾滋病恶性财团(AMC)进行了研究,以改善艾滋病毒疾病的癌症治疗。 AMC集团主席办公室负责协调和监督AMC功能的各个方面。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

RONALD T. MITSUYASU其他文献

RONALD T. MITSUYASU的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('RONALD T. MITSUYASU', 18)}}的其他基金

Studies on the Prevalence, Risk Factors and Outcomes of Cancers in HIV in India
印度艾滋病毒感染者癌症患病率、危险因素和结果的研究
  • 批准号:
    8710116
  • 财政年份:
    2013
  • 资助金额:
    $ 25.01万
  • 项目类别:
Studies on the Prevalence, Risk Factors and Outcomes of Cancers in HIV in India
印度艾滋病毒感染者癌症患病率、危险因素和结果的研究
  • 批准号:
    8539193
  • 财政年份:
    2013
  • 资助金额:
    $ 25.01万
  • 项目类别:
South American Prevention of HIV Research Training Program (SAPHIR)
南美艾滋病毒预防研究培训计划 (SAPHIR)
  • 批准号:
    8474842
  • 财政年份:
    2011
  • 资助金额:
    $ 25.01万
  • 项目类别:
South American Prevention of HIV Research Training Program (SAPHIR)
南美艾滋病毒预防研究培训计划 (SAPHIR)
  • 批准号:
    8209934
  • 财政年份:
    2011
  • 资助金额:
    $ 25.01万
  • 项目类别:
South American Prevention of HIV Research Training Program (SAPHIR)
南美艾滋病毒预防研究培训计划 (SAPHIR)
  • 批准号:
    8309930
  • 财政年份:
    2011
  • 资助金额:
    $ 25.01万
  • 项目类别:
AMC Group Chairman, University of California, LA
AMC 集团董事长,加州大学洛杉矶分校
  • 批准号:
    8099873
  • 财政年份:
    2010
  • 资助金额:
    $ 25.01万
  • 项目类别:
Network Core Research Lab
网络核心研究实验室
  • 批准号:
    8099897
  • 财政年份:
    2010
  • 资助金额:
    $ 25.01万
  • 项目类别:
UCLA-USC Combined Los Angeles Core Site
加州大学洛杉矶分校 (UCLA)-南加州大学 (USC) 联合洛杉矶核心站点
  • 批准号:
    8099881
  • 财政年份:
    2010
  • 资助金额:
    $ 25.01万
  • 项目类别:
A SINGLE ARM, OPEN-LABEL PILOT TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A QUADR
Quadr 安全性和免疫原性的单臂、开放标签试点试验
  • 批准号:
    7951594
  • 财政年份:
    2009
  • 资助金额:
    $ 25.01万
  • 项目类别:
PHASE IIA TRIAL OF 1% TOPICAL CIDOFOVIR FOR TREATMENT OF HIGH-GRADE PERIANAL SQU
阶段%20IIA%20试验%20OF%201%%20局部%20西多福韦%20FOR%20治疗%20OF%20高等级%20肛周%20SQU
  • 批准号:
    8167120
  • 财政年份:
    2009
  • 资助金额:
    $ 25.01万
  • 项目类别:

相似海外基金

Epigenetic Rejuvenation of Human Beta-Cells
人类β细胞的表观遗传复兴
  • 批准号:
    8811498
  • 财政年份:
    2014
  • 资助金额:
    $ 25.01万
  • 项目类别:
Islet Dysregulation in Infants with Congenital Hyperinsulinism
先天性高胰岛素血症婴儿的胰岛失调
  • 批准号:
    9249526
  • 财政年份:
    2014
  • 资助金额:
    $ 25.01万
  • 项目类别:
Islet Dysregulation in Infants with Congenital Hyperinsulinism
先天性高胰岛素血症婴儿的胰岛失调
  • 批准号:
    8826730
  • 财政年份:
    2014
  • 资助金额:
    $ 25.01万
  • 项目类别:
Islet Dysregulation in Infants with Congenital Hyperinsulinism
先天性高胰岛素血症婴儿的胰岛失调
  • 批准号:
    8764054
  • 财政年份:
    2014
  • 资助金额:
    $ 25.01万
  • 项目类别:
Proj. 4-The Genetic Variation of Innate Immune Genes w/Oral Manifestations of HIV
项目。
  • 批准号:
    8377539
  • 财政年份:
    2012
  • 资助金额:
    $ 25.01万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了